Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fardous F. El-Senduny has a total of 177 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Platelet-rich plasma ameliorates dexamethasone-induced myopathy by suppressing autophagy and enhancing myogenic potential through modulation of Myo-D, Pax-7, and myogenin expression

    by Sally M. Safwat, Dalia M. Abdel Ghaffar, Mamdouh Eldesoqui, Sally Abdallah Mostafa, Eman A.E. Farrag, Fardous El-Senduny, Basma Osman, Eman Mohamad El Nashar, Shaker Hassan Alshehri, A. Alhefzi, et al.


  • Open Access

    Design, biological evaluation, and molecular modelling insights of cupressic acid derivatives as promising anti-inflammatory agents

    by Amal F. Soliman, Diaaeldin M. Elimam, Fardous F. El-Senduny, Manal A. Alossaimi, Mubarak Alamri, Fatma M. Abdel Bar

    The major labdanes in the oleogum resin of Araucaria heterophylla (Salisb.) Franco, 13-epi-cupressic acid (1) and acetyl-13-epi-cupressic acid (2) were used to prepare seven new (3–9), along with one known (10) derivatives. RAW264.7 cells were used to evaluate the anti-inflammatory activity of the derivatives (1–10) via measuring the level of COX-2 expression and IL-6. Pre-treated RAW264.7 cells with 1–10 (except for derivative 7) at 25 µM for 24h exhibited downregulation of COX-2 expression in response to LPS stimulation. Moreover, pre-treatment with compounds 1, 2, or 3 significantly attenuated the LPS-stimulated IL-6 level in RAW264.7 cells (p < 0.05). A docking study was conducted against phospholipase A2 (PLA2), a crucial enzyme in initiating the inflammatory cascade. The significant structural features of compounds (1–10) as PLA2 inhibitors included the carbonyl group at C-4 (free or substituted) and the hydrophobic diterpenoid skeleton. This study suggested 13-epi-cupressic acid as a scaffold for new anti-inflammatory agents.


  • Retracted

    RETRACTED ARTICLE: Efficient chemosensitizing and antimetastatic combinations of a naturally occurring trans-ferulic acid with different chemotherapies on an in vitro hepatocellular carcinoma model

    by Nabil Mohie Abdel-Hamid, Nadia A. ElNakeeb, Fardous F. El-Senduny

    Trans-ferulic acid (TFA) is a polyphenolic compound present in many dietary supplements. The aim of this study was to get better chemotherapeutic outcomes through treatment protocols for human hepatocellular carcinoma (HCC). This study focused on the exploration of the in vitro influence of a combination of TFA with 5-fluorouracil (5-FU), doxorubicin (DOXO), and cisplatin (CIS) on HepG2 cell line. Treatment with 5-FU, DOXO, and CIS alone down-regulated oxidative stress and alpha-fetoprotein (AFP), and decreased cell migration through the depression of metalloproteinases (MMP-3, MMP-9, and MMP-12) expression. Co-treatment with TFA synergized the effects of these chemotherapies by decreased MMP-3, MMP-9, and MMP-12 expression, and gelatinolytic activity of both MMP-9 and MMP-2 in cancer cells. TFA significantly reduced the elevated levels of AFP and NO, and depressed cell migration ability (metastasis) in HepG2 groups. Co-treatment with TFA elevated the chemotherapeutic potency of 5-FU, DOXO, and CIS in managing HCC. Graphical Abstract


  • Open Access

    Down regulation of fatty acid synthase via inhibition of PI3K/AKT/mTOR in ovarian cancer cell line by novel organoselenium pseudopeptide

    by Abeer M. El-Saudi, Miram A. Altouhamy, Saad Shaaban, Farid A. Badria, Magdy M. Youssef, Fardous F. El-Senduny


  • Synthesis of new thienylnicotinamidines: Proapoptotic profile and cell cycle arrest of HepG2 cells

    by Mohamed A. Ismail, Ghada A. Abdelwahab, Wafaa S. Hamama, Ehab Abdel‐Latif, Fardous F. El‐Senduny, Wael M. El‐Sayed

    Fourteen new thienylnicotinamidines and their analogs 5a–5k, 12, 13a, and 13b were prepared and their antiproliferative potential was evaluated against the growth of 60 cancer cell lines. The tested compounds had a strong antiproliferative efficacy against almost all cancer cell lines, with the average GI50 at ~2.20 µM. The effect of the thienylnicotinamidines on the growth of normal lung fibroblast cells (WI‐38) indicated that these derivatives are safe to the normal cells. The selectivity index (SI) ranges from 5.5‐ to 42.0‐fold. The conceivable mechanisms of action of the effective compounds 5d, 5f, 5g, 5i, 5j, and 5k with high SI were investigated. Although the thienylnicotinamidines are similar in structure, they could be divided into three groups as per their effects on gene expression: The first group (5d and 5f) elevated p53 and caspase 3 expression, the second group (5g and 5i) elevated p53 expression, and the last group (5j and 5k) elevated p53 and reduced topoII expression. Many thienylnicotinamides inhibited the vascular endothelial growth factor receptor‐2 (VEGFR‐2) in cell lysates at concentrations comparable to or better than pazopanib. The data of caspase 3 expression were confirmed by measuring the protein level by Western blot and the activity of the cleaved active enzyme. The ability to arrest the cell cycle and induce apoptosis was confirmed by flow cytometry. Taken together, two derivatives, 5d and 5f, with a distinctive VEGFR‐2 inhibitory activity and a proapoptotic and cell cycle arrest profile merit further investigations.


  • Open Access

    Rapamycin Improves Adipose-Derived Mesenchymal Stem Cells (ADMSCs) Renoprotective Effect against Cisplatin-Induced Acute Nephrotoxicity in Rats by Inhibiting the mTOR/AKT Signaling Pathway

    by Amira Awadalla, Abdelaziz M. Hussein, Yousra M. El-Far, Fardous F. El-Senduny, Nashwa Barakat, Eman T. Hamam, Hanaa M. Abdeen, Mohamed El-Sherbiny, Mohamed S. Serria, Amira A. Sarhan, et al.

    Objective: Because the poor survival of transplanted cells in a hostile microenvironment limits stem cell therapy, in the current study, we investigated the effect of rapamycin (Rapa)-preactivated autophagy on the survival and homing of transplanted adipose mesenchymal stem cells (ADMSCs) in a rat model of cisplatin (Cis)-induced nephrotoxicity, as well as the possible role of the mTOR/AKT signaling pathway. Materials and methods: In vitro, ADMSCs isolated from rats were treated with 50 nmol/L rapamycin for 2 h, after which the cytoprotective and autophagy-inducing effects of Rapa were investigated. The cis-induced acute nephrotoxicity rat model was constructed in vivo. ADMSCs and Rapa-ADMSCs were administered into the tail vein before Cis therapy. At 3, 7, and 10 days after Cis injection, all animals were euthanized. The renal functions and morphology as well as autophagy response were assessed. Results: The pretreatment of cultured ADMSCs with Rapa caused a significant increase in autophagic activities and lysosome production of the cells, with a significant increase in the secretion of SDF-1, IL-10 and autophagy promoter LC3 and Beclin from these cells, while mTOR/AKT pathways were inhibited. In addition, the transplantation of Rapa-pretreated ADMSCs restored the kidney functions and morphology dramatically. Renal expression of SDF-1 and HIF1 was upregulated, while expression of IL-6, NF-kB and TGF-β1 was downregulated. Conclusions: We concluded that the preactivation of autophagy with Rapa improves the survival and differentiation of the transplanted ADMSCs by inhibiting the mTOR/AKT signaling pathway, which in turn could significantly attenuate the Cis-induced acute renal injury.


  • Open Access

    Design, Synthesis, and Biological Evaluation of a Novel VEGFR-2 Inhibitor Based on a 1,2,5-Oxadiazole-2-Oxide Scaffold with MAPK Signaling Pathway Inhibition

    by Mater H. Mahnashi, Fardous F. El-Senduny, Mohammed Abdulrahman Alshahrani, Mahrous A. Abou-Salim

    Over the past few decades, the development of broad-spectrum anticancer agents with anti-angiogenic activity has witnessed considerable progress. In this study, a new series of pyrazolo[3,4-d]pyrimidines based on a phenylfuroxan scaffold were designed, synthesized, and evaluated, in terms of their anticancer activities. NCI-60 cell one-dose screening revealed that compounds 12a–c and 14a had the best MGI%, among the tested compounds. The target fluorinated compound 12b, as the most active one, showed better anticancer activity compared to the reference drug sorafenib, with IC50 values of 11.5, 11.6, and 13 µM against the HepG-2, A2780CP, and MDA-MB-231 cell lines, respectively. Furthermore, compound 12b (IC50 = 0.092 µM) had VEGFR-2-inhibitory activity comparable to that of the standard inhibitor sorafenib (IC50 = 0.049 µM). Furthermore, the ability of compound 12b in modulating MAPK signaling pathways was investigated. It was found to decrease the level of total ERK and its phosphorylated form, as well as leading to the down-regulation of metalloproteinase MMP-9 and the over-expression of p21 and p27, thus leading to subG1 cell-cycle arrest and, thus, the induction of apoptosis. Additionally, compound 12b decreased the rate of wound healing in the absence of serum, in comparison to DMSO-treated cells, providing a significant impact on metastasis inhibition. The quantitative RT-PCR results for E-cadherin and N-cadherin showed lower expression of the neuronal N-cadherin and increased expression of epithelial E-cadherin, indicating the ability of 12b to suppress metastasis. Furthermore, 12b-treated HepG2 cells expressed a low level of anti-apoptotic BCL-2 and over-expressed proapoptotic Bax genes, respectively. Using the DAF-FM DA fluorescence probe, compound 12b produced NO intracellularly as efficiently as the reference drug JS-K. In silico molecular docking studies showed a structural similarity through an overlay of 12b with sorafenib. Interestingly, the drug-likeness properties of compound 12b met the expectations of Pfizer’s rule for the design of new drug candidates. Therefore, this study presents a novel anticancer lead compound that is worthy of further investigation and activity improvement.


  • Open Access

    Purification and characterization of a caseinolytic enzyme from Bacillus subtilis.

    by Ebtesam Elkenawi, A Elsayed, Fardous El-Senduny, Magdy Youssef, M Magdy

    Nattokinase (EC 3.4.21.62) is a serine protease and profibrinolytic enzyme with a strong fibrin-degrading activity, and many host strains can produce it. By its comparison with other fibrinolytic enzymes such as (streprokinase, urokinase and t-PA), nattokinase showed many advantages of having long life-time, no side effects, costless and it owns the ability to be a drug candidate for treatment of heart diseases and used as an effective food additive. Bacillus subtilis natto discovered in natto, a typical Japanese fermented soybean food. After the purification of Nattokinase from the supernatant of B. subtilis culture media, it showed a strong fibrinolytic activity. The enzyme was refined to a 4.4-fold purity level, with 61.8 percent of activity recovered. SDS-PAGE showed that nattokinase is homogenous and identified it as a monomer of 29000 Da in its original state. The optimum temperature and pH were 65°c and 9.0 respectively. Purified nattokinase is thermally stable at temperatures ranging from 35 to 55 °C and alkaline stable at pH 7.0 to 10.0. Skim milk agar showed clear zone of crude enzyme. Mg2+ increased the activity of nattokinase, but Zn2+ and Fe3+ decreased the activity. Triton x-100 as detergent significantly increased activity of nattokinase on the contrast to SDS inhibit nattokinase activity.

  • Open Access

    Impact of gene polymorphism of glutathione S-transferase and ghrelin as a risk factor in Egyptian women with gestational diabetes mellitus

    by Mai M. Madkour, Afaf M. El-Said, Abd El-Aziz A. El-Refaey, Abd El-Aziz F. Abd El-Aziz, Fardous F. El-Senduny